BioSig Technologies Makes Bold Pivot Into Blockchain With Streamex Acquisition

Medical tech firm repositions around real-world asset tokenization, signaling a dramatic strategic shift

BioSig Technologies Inc. (NASDAQ: BSGM), historically known for its cardiac electrophysiology technology, has taken a transformative step into the blockchain world with the acquisition of Streamex Exchange Corporation.

Through a definitive share exchange agreement, Streamex will become a wholly owned subsidiary of BioSig—marking the company's entry into the rapidly emerging market of tokenized real-world assets (RWAs).

Pending shareholder approval, the transaction will result in Streamex shareholders owning 75% of BioSig’s fully diluted common stock. In line with regulatory limits, 19.9% of the shares have already been issued to Streamex investors, with the balance subject to closing conditions.

Leadership Overhaul Reflects Strategic Shift

As part of the transition, Streamex’s co-founder Henry McPhie will assume the role of CEO of the combined entity, while Morgan Lekstrom will take over as Chairman. Current BioSig CEO Anthony Amato will move to the board of directors—further cementing the company’s pivot away from its legacy in medical device innovation toward digital asset infrastructure.

Entering a $140 Trillion Market with Tokenization Ambitions

This move positions BioSig to participate in the estimated $142 trillion global market for tokenized real-world assets—a space increasingly seen as the future of commodity trading and finance.

Streamex’s vertically integrated infrastructure is designed to modernize how commodities are traded, bringing greater efficiency, transparency, and speed through blockchain-based settlement systems.

Industry veterans have taken notice. The new advisory board includes prominent names such as Frank Giustra (founder of Wheaton Precious Metals and GoldCorp), signaling confidence in the company’s revised vision.

Their backing underscores the strategic ambition behind this pivot: to become a first mover in digitizing commodity finance.

Risk and Uncertainty in a High-Reward Shift

While the upside of tokenization is significant, the shift also introduces new challenges. BioSig shareholders face dilution, and the company must now navigate a sector with vastly different technical and regulatory complexities.

As of now, Streamex has not publicly detailed its blockchain architecture or token mechanics—leaving open questions about execution.

Institutional interest in BioSig has spiked in recent months, with data showing a 218% increase in institutional transactions over the last six months. However, insider activity has remained flat—a sign that internal sentiment may be cautious amid the transition.

Looking Ahead

BioSig’s acquisition of Streamex represents more than a change in direction—it’s a redefinition of the company’s identity.

Whether the market rewards this bold move will depend on Streamex’s ability to deliver a competitive product in a fast-moving, complex space.

For investors, the opportunity lies in being early to what could be a powerful blockchain-driven reinvention—but the usual caveats around execution risk and market timing still apply.

As tokenization continues to gain momentum in finance, BioSig’s evolution will be a case study in how traditional companies can attempt to reinvent themselves for the digital era.

Disclaimer: Cashu Technologies Pty Ltd. has been compensated by BioSig Technologies Inc. to create and distribute this promotional content. While reasonable efforts have been made to ensure the accuracy and reliability of the information presented, no representation or warranty is made as to its completeness or timeliness. Any investment decision made based on the content of this newsletter is done at your own risk. Cashu Technologies Pty Ltd. expressly disclaims any and all liability for any loss or damage arising from reliance on the information provided herein.